5264-15-3

Basic information

• Product Name: 4-PYRIDIN-4-YL-BUTAN-1-OL
• Synonyms: 4-PYRIDIN-4-YL-BUTAN-1-OL;AURORA KA-2522;4-(4-Pyridinyl)-1-butanol;4-Pyridinebutane-1-ol;4-(4-Pyridinyl)butanol;4-Pyridinebutanol;Zinc03953272;4-Pyridine Butyl Alcohol
• CAS NO: 5264-15-3
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Mol File: 5264-15-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 290.9 °C at 760 mmHg
• Flash Point: 129.7 °C
• Appearance: /
• Density: 1.036 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 15.09±0.10(Predicted)
• CAS DataBase Reference: 4-PYRIDIN-4-YL-BUTAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PYRIDIN-4-YL-BUTAN-1-OL(5264-15-3)
• EPA Substance Registry System: 4-PYRIDIN-4-YL-BUTAN-1-OL(5264-15-3)

Safety Data

• Hazardous Substances Data: 5264-15-3(Hazardous Substances Data)

Upstream product

• 84200-10-2 ethyl 4-(pyridin-4-yl)butanoate 
• 192643-83-7 4-(pyridin-4-yl)butyl-3-yn-1-ol 
• 1120-87-2 4-bromopyridin 
• 84200-09-9 4-(3-cyanopropyl)pyridine 
• 5264-02-8 3-(4-pyridyl)-1-chloropropane 
• 120690-80-4 3-(pyridin-4-yl)propionaldehyde 
• 108-89-4 picoline 
• 4343-98-0 4-[4-(Tetrahydro-pyran-2-yloxy)-butyl]-pyridine 
• 102878-73-9 γ-(pyridin-4-yl)butyric acid 
• 100-43-6 4-vinylpyridine 

Downstream Products

• 5264-17-5 4-(pyridin-4-yl)-1-chlorobutane 
• 57614-92-3 4-(piperidin-4-yl)butan-1-ol 
• 149490-61-9 N-(n-butanesulfonyl)-O-(4-(4-pyridinyl)-butyl)-(S)-tyrosine 
• 144494-65-5 tirofiban hydrochloride 
• 263390-99-4 2-(3-bromophenylthio)-3-(4-(pyridin-4-yl)butoxy)pyridine 
• 192643-84-8 4-(pyridin-4-yl)butyraldehyde 
• 192643-82-6 [2-[2-(3,5-dimethylphenyl)-5-(morpholine-4-carbonyl)-1H-indol-3-yl]ethyl]-(4-pyridin-4-ylbutyl)carbamic acid benzyl ester 

Relevant articles and documents

Synthesis method of tirofiban hydrochloride intermediate III (by machine translation)

The invention belongs to the field, of medicine synthesis, and particularly relates to a synthesis method III of tirofiban hydrochloride intermediate. by, reduction of an intermediate I under the action of a sodium borohydride reducing system to obtain intermediate II, intermediate II under Lewis acid chloride in the presence. SOCl2 Reaction conditions of, process are mild III, and N - process operation is simple, the reaction conditions of the reaction yield, product are improved, the product purity is high, and the reaction yield is increased by, times without being subjected to column purification, to improve the clinical medication safety, of the injection using, the standard crude drug product of the pharmacopoeia standard, and is suitable, for industrial production. (by machine translation)

Synthesis and biological evaluation of PEG-tirofiban conjugates

We have conjugated tirofiban, an antagonist of the GPIIb/IIIa integrin receptor, to PEG, and shown that these polymers effectively inhibit platelet aggregation. This inhibition decreased with the size of the polymer. Our goal was to develop new cryoprotec

2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation

A compound of the formula (I) wherein A is O, S, CHR1or NR2, R1and R2are H, lower alkyl, X1and X2are H, halogen, nitro, cyano, etc., Y1is H, lower alkyl, Z1and Z2are H, halogen, cyano, hydroxy, lower alkyl, etc., and n is an integer of 2 to 4, a pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and an intermediate therefor. The compounds (I) of the present invention show a potent PDE IV inhibitory activity as well as an excellent bronchodilating activity, and hence, they are widely useful as a PDE IV inhibitor in the treatment or prophylaxis of allergic inflammatory diseases or organ inflammatory diseases, especially in the treatment or prophylaxis of pulmonary diseases accompanied by airway obstruction such as asthma.